Elevance Health (ELV) Stock Looks Reasonable On Earnings But Stretched After 25% Gain

Elevance Health stock has gained 24.7% over the past year, and the latest valuation checks still lean toward the shares looking inexpensive rather than stretched at recent levels.

• The 24.7% one year return suggests investors have already been willing to pay more for Elevance Health, yet the current pricing still leaves room for the question of whether the stock fully reflects its fundamentals.
• Confidence around Elevance Health's margin outlook and efficiency efforts, alongside ongoing legal and regulatory uncertainty in key Medicare Advantage and government programs, can both influence how much investors are prepared to pay for the stock.
• With Elevance Health screening as undervalued in 5 of 6 key checks, the broader valuation workup leans cheap rather than fully pricing in the recent share price strength, according to its 5/6 value score.

The issue now is whether Elevance Health's recent gains have simply closed an earlier discount or if the stock still offers mispriced value at today's level.

Find out why Elevance Health's 24.7% return over the last year is lagging behind its peers.

Is Elevance Health Still Cheap on Earnings?

The P/E ratio is a useful yardstick for Elevance Health because earnings are a central focus for many investors in large health insurers. Elevance Health currently trades on a P/E of 17.2x, which is below both the Healthcare sector average of 24.9x and a peer group average of 43.1x, so the stock screens as cheaper than many comparable companies on an earnings basis.

The tailored fair P/E ratio for Elevance Health is 33.5x. This figure reflects what investors might expect to pay given its sector, business profile, and risk factors. That is almost double the current 17.2x multiple. On this comparison, the stock does not appear to fully reflect the valuation level implied by this framework. Although sentiment around Elevance Health has seen a recent uplift after analysts highlighted a strong margin outlook, the P/E still sits well below both the fair ratio and peer benchmarks.

On this earnings multiple comparison, Elevance Health stock appears undervalued on a relative basis.

See what the numbers say about this price — find out in our valuation breakdown.

The Elevance Health Narrative: What Would Justify Today's Price?

For Elevance Health, Simply Wall St Narratives pick up where the valuation puzzle leaves off by spelling out the future assumptions on growth, margins, and earnings that would need to be true for the stock to be worth meaningfully more or less than it is today on the market. Rather than focusing on a single multiple or model output, each narrative lays out the key drivers behind its implied value so you can compare those expectations with Elevance Health's actual results over time.

Community views on Elevance Health sit far apart, with one side focused on margin recovery potential and the other on government plan and policy risk.

Bull case: roughly fairly valued

"Strategic investments in digital consumer engagement and Carelon's diversified health services (e.g., pharmacy, care management, behavioral health) are accelerating revenue growth and providing higher-margin, recurring income streams..."

Read the full Bull Case to see why Elevance Health could be undervalued

Bear case: 26% overvalued

"Elevated costs in government-backed plans and greater reliance on value-based care could compress margins despite operational improvements and diversification strategies..."

Read the full Bear Case to see why Elevance Health could be overvalued

Do you think there's more to the story for Elevance Health? Head over to our Community to see what others are saying!

The Bottom Line

Elevance Health still screens as undervalued on market multiples, which suggests the current price does not fully reflect what investors are paying for similar healthcare stocks. The broader valuation checks also lean supportive, but they sit against a backdrop of ongoing legal and regulatory questions around key government programs. For you, the real hinge is whether Elevance Health can sustain its margin and efficiency story without a negative surprise from Medicare Advantage or policy changes, which would determine whether the current discount is an opportunity or a warning.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com